Leading pharmaceutical manufacturer plans to strengthen presence in Missouri

Gov. Jay Nixon today praised plans by Mallinckrodt, a leading global provider of specialty pharmaceuticals, to strengthen its presence in Missouri. As part of its spinoff from former parent company Covidien, Mallinckrodt plans to invest $2 million in its U.S. headquarters in Hazelwood, creating 150 new jobs in the area.

The spinoff makes Mallinckrodt one of the largest public companies in St. Louis. The company is incorporated in Ireland and began officially trading on the New York Stock Exchange today. Mallinckrodt’s facility in Hazelwood is, and will remain, its U.S. headquarters. Mallinckrodt currently employs approximately 2,500 workers in the St. Louis area, and has more than 5,500 employees globally.

[Missouri Governor Jay Nixon]